Clinical trials: Stereotactic Body Radiation Therapy
Cancer of Ovary, Cancer of the Ovary
MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer
The investigators propose to evaluate the feasibility, safety, and preliminary efficacy of delivering online, adaptive magnetic resonance imaging (MRI)-guided and gated stereotactic body radiation therapy for patients with…
- Conditions
- Cancer of Ovary, Cancer of the Ovary, Neoplasms, Ovarian, Ovarian Cancer
- Trial name
- NCT02582931
- Testing
- MRI-guided SBRT, EORTC QLQ-C30 Questionnaire, EORTC QLQ-OV28 Questionnaire
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Solid Tumor, Liver Metastases
Individualized Stereotactic Body Radiotherapy of Liver Metastases
Stereotactic body radiation therapy (SBRT) is a technique that is used to deliver radiation, to sites in the body. All participants in this study will be treated with SBRT using proton beam radiation.
- Trial name
- NCT01239381
- Testing
- Stereotactic body radiotherapy-proton
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- Massachusetts General Hospital
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer
This phase II trial studies the how well apalutamide with or without stereotactic body radiation therapy work in treating participants with castration-resistant prostate cancer.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
- Trial name
- PILLAR (NCT03503344)
- Testing
- Apalutamide, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of California, San Francisco
Hepatocellular Carcinoma
A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
Patients on this study will self administer Prednisone for three days before starting Radiation Therapy (RT) and continue to take 60 mg/day during the first three fractions of RT.
- Trial name
- NCT05901519
- Testing
- Prednisone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostate Adenocarcinoma
Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer
You have been asked to consider participating in the study because you have a cancer of the prostate, which is to be treated with external beam radiation.
- Trial name
- 2STAR (NCT02031328)
- Testing
- Stereotactic Ablative Radiation
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Sunnybrook Health Sciences Centre
Liver Neoplasms, Liver Metastases
SBRT for Liver Tumors, Liver Metastases, and Pancreatic Tumors
This prospective observational study evaluates the safety and effectiveness of stereotactic body radiotherapy (SBRT) for liver tumors, liver metastases, and pancreatic tumors.
- Conditions
- Liver Neoplasms, Liver Metastases, Pancreatic Neoplasms
- Trial name
- NCT07407257
- Testing
- Stereotactic Body Radiotherapy (SBRT)
- Where
- Slovenia
- Volunteers
- 65 people
- Sponsor
- Institute of Oncology Ljubljana
Prostatic Cancer, Castration-Resistant
Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
In earlier stages of prostate cancer, male sexual hormones (androgens) stimulate the growth of cancer cells. Castration-resistant prostate cancer (CRPC) means that the prostate cancer continued to grow despite patients are taking…
- Trial name
- PEACE8 (NCT06276465)
- Testing
- Darolutamide 300 mg, Stereotactic body radiation therapy, Androgen deprivation therapy
- Where
- 4 sites in France
- Volunteers
- 336 people
- Sponsor
- UNICANCER
Metastatic Clear Cell Renal Cell Carcinoma
High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
In this i-SABR (immunotherapy + Stereotactic Ablative Body Radiation) trial, the stereotactic radiation to multiple metastatic sites is delivered not only to eradicate sites of bulky progressive disease, but also to provide…
- Trial name
- NCT01896271
- Testing
- IL-2, Stereotactic Ablative Body Radiation Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Texas Southwestern Medical Center
Prostate Cancer
Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin
This phase I/II escalation dose study is assessing the efficacy of the recommended dose of stereotactic re-irradiation (SBRT) of relapses within the prostatectomy bed, potentiated by metformin
- Trial name
- REPAIR (NCT04536805)
- Testing
- Metformin, Stereotactic Body Radiation Therapy (SBRT) 30 Gray (Gy), Stereotactic Body Radiation Therapy (SBRT) 36 Gy
- Where
- 12 sites in France
- Volunteers
- 44 people
- Sponsor
- Institut Cancerologie de l'Ouest
Breast Cancer, Recurrent Breast Cancer
Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer
Local treatment in addition to endocrine treatment as 1st line for oligo-metastatic ER-positive/HER2-negative breast cancer.
- Conditions
- Breast Cancer, Recurrent Breast Cancer, Stereotactic Body Radiotherapy, Estrogen Receptor Positive Tumor
- Trial name
- CLEAR (NCT03750396)
- Testing
- Surgical resection, Stereotactic body radiotherapy, Radiofrequency ablation
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Gangnam Severance Hospital
Prostate Cancer Metastatic
ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer
The purpose of this study is to evaluate the safety of combining Actinium- J591 with radiation therapy or with androgen deprivation therapy.
- Trial name
- ACTION (NCT05567770)
- Testing
- Actinium-J591, Stereotactic Body Radiation Therapy, Androgen Deprivation Therapy
- Sponsor
- Weill Medical College of Cornell University
Lung Squamous Cell Carcinoma
Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer
This is a randomized, controlled, open-label, multicenter phase II clinical trial comparing the efficacy and safety of low-dose radiation therapy and stereotactic body radiation therapy combined with PD-1 inhibitor (sintilimab)…
- Trial name
- NCT06121505
- Testing
- low-dose radiation therapy and stereotactic body radiation therapy, chemotherapy, Sintilimab
- Where
- 6 sites in China
- Volunteers
- 114 people
- Sponsor
- Sichuan University
Pancreatic Neoplasms
SBRT Pre-operatively for Pancreatic Cancer
In this study the investigators are testing if the addition of Stereotactic Body Radiation therapy (SBRT) prior to surgery improves surgical outcome in patients with borderline resectable or resectable pancreatic cancer (BRPC).
- Trial name
- SPARC (NCT02308722)
- Testing
- 5-fraction stereotactic body radiation therapy
- Where
- 5 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- University of Oxford
Peripherally Located Stage I Lung Cancer, Peripherally Located Solitary Lung Metastasis
Lung Stereotactic Body Radiotherapy (SBRT) Delivered Over 4 Days Versus 11 Days
Stereotactic Body Radiotherapy (SBRT) has emerged as a new treatment option for peripherally located lung tumours, offering very high rates of tumour eradication, with minimal side effects.
- Trial name
- NCT01620034
- Testing
- Stereotactic Body Radiotherapy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Sunnybrook Health Sciences Centre
Soft Tissue Sarcoma, Stereotactic Body Radiotherapy
Safety and Efficacy of Preoperative SBRT and Radical Surgery for Soft Tissue Sarcoma of Extremities
Currently, the effectiveness and safety of preoperative hypo-fractionated radiotherapy in treating extremity soft tissue sarcomas remain inconclusive, warranting further investigation.
- Conditions
- Soft Tissue Sarcoma, Stereotactic Body Radiotherapy, Surgery
- Trial name
- NCT06760221
- Testing
- stereotactic body raiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC
This is a multicenter, randomized, open-label phase 2 study for men with metastatic hormone-sensitive prostate cancer. About 254 participants will first receive 6 months of darolutamide plus androgen deprivation therapy.
- Trial name
- PSMA-DaroRT (NCT07649421)
- Testing
- Stereotactic Body Radiotherapy (SBRT), Darolutamide 600 mg twice daily, Androgen Deprivation Therapy (ADT)
- Where
- China
- Volunteers
- 254 people
- Sponsor
- West China Hospital
Liver Neoplasms, Hepatocellular Cancer
Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)
This will be multicentre a phase II randomized controlled and open-label trial. It will compare the 6-months objective response (CR+PR) rates obtained with Drug Eluting Bead Trans-Arterial Chemo-Embolization (DEB-TACE) alone…
- Trial name
- HepSTAR (NCT02958163)
- Testing
- Trans-arterial Chemo-Embolization, Doxorubicin, Stereotactic Ablative Radiotherapy
- Where
- 5 sites in Belgium
- Volunteers
- 3 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma
Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer
This phase II trial tests how well stereotactic body radiation therapy (SBRT) works in treating patients with estrogen receptor positive (ER +) breast cancer that has spread from where it first started to other places in the body…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, Metastatic Breast Carcinoma
- Trial name
- NCT06260033
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
NSCLC, Stereotactic Body Radiation Therapy (SBRT)
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
Introduction: Immunotherapy in combination with chemotherapy have been recommended as the first-line treatment of driver-negative advanced non-small cell lung cancer (NSCLC), but the efficacy is worse in NSCLC patients with bone…
- Conditions
- NSCLC, Stereotactic Body Radiation Therapy (SBRT), Immunotherapy
- Trial name
- NCT06738160
- Testing
- Narlumosbart, Stereotactic Body Radiation Therapy
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Fudan University
Thyroid Cancer Stage IV
Stereotactic Body Radiotherapy for the Treatment of Distant Metastases in Thyroid Cancer: A Phase II Prospective Clinical Study
The goal of this observational study is to evaluate the efficacy and safety of Stereotactic Body Radiotherapy in the treatment of distant metastatic thyroid cancer.
- Trial name
- NCT07755423
- Testing
- SBRT
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.